Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Inclusion Criteria: - Subjects diagnosed with type 2 diabetes and on stable diabetestreatment with 1-2 OADs (Metformin equal to or above 1500 mg or maximum tolerated doseand/or thiazolidinedione (TZD) and sulfonylureas (SUs) equal to or above half of maximumdose allowed according to national label) for at least 90 days prior to screening. Stableis defined as unchanged medication and unchanged dose - HbA1c 7.0 - 10.5 % (53 - 91

mmol/mol) (both inclusive) Exclusion Criteria: - Females of childbearing potential who arepregnant, breast-feeding or intend to become pregnant or are not using an adequatecontraceptive method throughout the trial including the 5 week follow-up period (adequatecontraceptive measures as required by local law or practice) - Any chronic disorder orsevere disease which, in the opinion of the investigator, might jeopardise subject's safetyor compliance with the protocol - Treatment with glucose lowering agent(s) other thanstated in the inclusion criteria in a period of 90 days before screening. An exception isshort-term treatment (7 days or less in total) with insulin in connection withinter-current illness - History of chronic or idiopathic acute pancreatitis - Screeningcalcitonin value equal to or above 50 ng/L (pg/mL) - Personal or family history ofmedullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) -Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60ml/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variableversion) - Acute coronary or cerebrovascular event within 90 days before randomisation -Heart failure, New York Heart Association (NYHA) class IV